Quince Therapeutics, Inc. (QNCX) Financials

QNCX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 124.0 million 159.3 million
March 31, 2026 26.6 million 11.0 million
Dec. 31, 2025 93.5 million 129.2 million
Sept. 30, 2025 109.9 million 108.8 million

QNCX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -18.9 million 12.1 million
March 31, 2026 -7.6 million 1.3 million
Dec. 31, 2025 -10.5 million 1.2 million
Sept. 30, 2025 -10.0 million 1.3 million

QNCX Net Income

No data available :(

QNCX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 116.0 million - -
March 31, 2026 18.2 million - 293000
Dec. 31, 2025 17.8 million - 445000
Sept. 30, 2025 26.3 million - 473000

QNCX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 6.1 million
March 31, 2026 250485
Dec. 31, 2025 278626
Sept. 30, 2025 269757

QNCX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 5.5 million 16.6 million -
March 31, 2026 4000 6.8 million 4.3 million -
Dec. 31, 2025 4000 12.6 million 3.6 million -
Sept. 30, 2025 74000 8.1 million 3.3 million -

QNCX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - 59.0 million
March 31, 2026 - 36000
Dec. 31, 2025 - -
Sept. 30, 2025 - 36000

QNCX

Price: $33.93

52 week price:
15.10
910.00

Earnings Per Share: -210.00 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 34.7 million

Links: